CPX-351与FLAG-Ida在不良心型AML和高危MDS中的随机比较:英国NCRI AML19试验
英国NCRI AML19试验高危队列随机比较CPX-351与FLAG-Ida用于年轻新诊断不良心型AML或高危MDS患者,共189例,中位年龄56岁。第2疗程后总缓解率CPX-351组64% vs FLAG-Ida组76%,多变量分析总生存无差异(13.3个月 vs 11.4个月)。CPX-351组无复发生存显著更长(中位22.1 vs 8.35个月),MDS相关基因突变探索性亚组中CPX-351组总生存显著更长(中位38.4 vs 16.3个月)。
要点
- 年轻不良心型AML/高危MDS中,CPX-351与FLAG-Ida总生存无显著差异(13.3 vs 11.4个月)。
- CPX-351组无复发生存显著更长,中位22.1 vs 8.35个月。
- MDS相关基因突变探索性亚组中CPX-351组总生存显著更长(38.4 vs 16.3个月)。
核心结论
- 年轻不良心型AML/MDS患者中,CPX-351与FLAG-Ida的总生存无显著差异。
研究设计与样本
- 英国NCRI AML19试验(ISRCTN78449203)高危队列随机比较CPX-351与FLAG-Ida,纳入年轻新诊断不良心型AML或高危MDS患者189例,中位年龄56岁。
主要发现
- 临床标准分类:49%为原发AML,20%为继发性AML,30%为高危MDS。
- MDS相关细胞遗传学异常见于73%患者,复杂核型见于49%,TP53为最常见突变基因(43%),MDS相关基因突变见于75例(44%)患者。
- 第2疗程后总缓解率(CR+CRi)CPX-351组64% vs FLAG-Ida组76%。
- 多变量分析总生存无差异(13.3个月 vs 11.4个月),无事件生存亦无差异。
- 无复发生存CPX-351组显著更长(中位22.1 vs 8.35个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS) compared with 7+3 chemotherapy in older patients with secondary acute myeloid leukemia (AML); to date, there have been no randomized studies in younger patients. The high-risk cohort of the UK NCRI AML19 trial (ISRCTN78449203) compared CPX-351 with FLAG-Ida in younger adults with newly diagnosed adverse cytogenetic AML or high-risk myelodysplastic syndromes (MDS). A total of 189 patients were randomized (median age, 56 years). Per clinical criteria, 49% of patients had de novo AML, 20% had secondary AML, and 30% had high-risk MDS. MDS-related cytogenetics were present in 73% of the patients, with a complex karyotype in 49%. TP53 was the most common mutated gene, in 43%. Myelodysplasia-related gene mutations were present in 75 (44%) patients. The overall response rate (CR + CRi) after course 2 was 64% and 76% for CPX-351 and FLAG-Ida, respectively. There was no difference in OS (13.3 months vs 11.4 months) or event-free survival in multivariable analysis. However, relapse-free survival was significantly longer with CPX-351 (median 22.1 vs 8.35 months). There was no difference between the treatment arms in patients with clinically defined secondary AML or those with MDS-related cytogenetic abnormalities; however, an exploratory subgroup of patients with MDS-related gene mutations had significantly longer OS with CPX-351 (median 38.4 vs 16.3 months). In conclusion, the OS of younger patients with adverse risk AML/MDS was not significantly different between CPX-351 and FLAG-Ida.
引用
- Othman J, Wilhelm-Benartzi C, Dillon R, et al. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Adv. 2023. PMID: 37171402. doi:10.1182/bloodadvances.2023010276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。